The Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) is a consortium that was established by the National Institute for Allergy and Infectious Diseases (NIAID) to undertake the immunologic research that will tackle the major scientific obstacles in the development of an effective HIV-1 vaccine. Over the next 7 years, the Duke CHAVI-ID will build on the progress that was made by the CHAVI consortium and apply state-of-the-art technologies and both immunologic and virologic tools to improve rational HIV-1 vaccine design. The vaccine strategy of the Duke CHAVI-ID is based on identifying and targeting novel HIV-1 vulnerabilities to B, T and NK cell immune responses and using this information to design vaccines that will induce protective immunity at the time and location of HIV-1 transmission.
The goal of the Duke CHAVI-ID is to design a practical preventive HIV-1 vaccine that incorporates protective innate, antibody and T cell-targeted immunogens. These immunogens will be designed to prevent HIV-1 transmission by inducing the following types of protective immune responses at the site of HIV-1 entry:
The Duke CHAVI-ID will be a component of the Global HIV-1 Vaccine Enterprise, which is comprised of outstanding investigators who employ state-of-the art technology to address the critical gaps in scientific knowledge through carefully designed, focused, and coordinated studies that are aimed at developing a successful HIV-1 vaccine.
For more information, please visit the Duke CHAVI-ID website: http://chavi-id-duke.org.